- Home
- CCM vs MRSN Comparison
CCM vs MRSN Comparison
Compare CCM & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCM
- MRSN
- Stock Information
- Founded
- CCM 1997
- MRSN 2001
- Country
- CCM China
- MRSN United States
- Employees
- CCM N/A
- MRSN N/A
- Industry
- CCM Medical/Nursing Services
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- CCM Health Care
- MRSN Health Care
- Exchange
- CCM Nasdaq
- MRSN Nasdaq
- Market Cap
- CCM 33.3M
- MRSN 37.0M
- IPO Year
- CCM 2009
- MRSN 2017
- Fundamental
- Price
- CCM $5.36
- MRSN $7.18
- Analyst Decision
- CCM
- MRSN Strong Buy
- Analyst Count
- CCM 0
- MRSN 4
- Target Price
- CCM N/A
- MRSN $63.67
- AVG Volume (30 Days)
- CCM 10.8K
- MRSN 138.9K
- Earning Date
- CCM 09-26-2025
- MRSN 08-13-2025
- Dividend Yield
- CCM N/A
- MRSN N/A
- EPS Growth
- CCM N/A
- MRSN N/A
- EPS
- CCM N/A
- MRSN N/A
- Revenue
- CCM $52,603,198.00
- MRSN $34,769,000.00
- Revenue This Year
- CCM N/A
- MRSN N/A
- Revenue Next Year
- CCM N/A
- MRSN $1.03
- P/E Ratio
- CCM N/A
- MRSN N/A
- Revenue Growth
- CCM N/A
- MRSN 16.14
- 52 Week Low
- CCM $3.80
- MRSN $5.21
- 52 Week High
- CCM $10.77
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- CCM 51.38
- MRSN 46.89
- Support Level
- CCM $5.15
- MRSN $5.21
- Resistance Level
- CCM $5.62
- MRSN $7.68
- Average True Range (ATR)
- CCM 0.40
- MRSN 0.53
- MACD
- CCM 0.06
- MRSN 0.11
- Stochastic Oscillator
- CCM 35.62
- MRSN 72.46
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.